QLT PhotoTherapeutics
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration in conjunction with lasers made by Coherent and Zeiss Humphrey Systems to activate the photodynamic therapy is announced April 13. Independent marketing of Coherent's Opal Photoactivator and Zeiss' Visulas 690 PDT lasers, which have only slightly different features, commenced immediately following approval. The Opal is priced in the $40,000-50,000 range and the Visulas is priced at $37,900-44,900, depending on configuration with or without a slitlamp
You may also be interested in...
QLT Looks Beyond Ophthalmology To Treat Skin Cancer With Visudyne
QLT expects to complete enrollment of its pivotal Visudyne trial for multiple basal cell carcinoma by year-end and envisions U.S. approval in 2005
QLT Looks Beyond Ophthalmology To Treat Skin Cancer With Visudyne
QLT expects to complete enrollment of its pivotal Visudyne trial for multiple basal cell carcinoma by year-end and envisions U.S. approval in 2005
Novartis, QLT Will Expand Visudyne Population Following Approvable Letter
Novartis Ophthalmics' submission to FDA of interim data analyses from a Phase II study evaluating its Visudyne photodynamic therapy to treat ocular histoplasmosis syndrome (OHS) is likely to secure approval of its supplemental new drug application.